BIO.B Bio-Rad Laboratories
Bio-Rad Laboratories earnings company data as of 10:00 AM ET 10/23
Limited consensus data for this ticker (thin coverage or data-plan limits).
Dates may be company-announced rather than sell-side consensus.
Calendar and recent prints remain the primary lens when available.
Scheduled
1 period, newest first, nothing reported yet. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 4 Nov | EPS | — | — | — |
| Rev | — | — | — |
Insider trades
Open-market buys and sales by BIO.B's executives, directors and 10% owners in the last 12 months, from their Form 4s
- None no insider bought on the open market
- $350K sold by 2 insiders outside a trading plan
- None no planned (10b5-1) sales
-
Eva Anette Engelhardt EVP, President, CDGSale$136K 550 shares at $246.54 61% of stakeTraded May 11 Filed May 13
-
James Barry EVP, President, LSGSale$214K 700 shares at $306.18 58% of stakeTraded Nov 6, 2025 Filed Nov 10, 2025
Also filed in the last 12 months, not counted as buying or selling: 29 option exercises and 25 share withholdings for taxes.
SEC filings
Recent issuer filings from EDGAR, 16 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| 8-K | 2.02,2.05,7.01,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 2.02,7.01,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| 8-K | 5.02,5.07,9.01 | Filing Doc | |
| SCHEDULE 13G/A | — | Filing Doc | |
| DEF 14A | DEFINITIVE PROXY STATEMENT | Filing Doc | |
| 8-K | 7.01 | Filing Doc | |
| 10-K | Filing Doc | ||
| 8-K | 2.02,7.01,9.01 | Filing Doc | |
| SCHEDULE 13D/A | — | Filing Doc | |
| SCHEDULE 13D/A | — | Filing Doc | |
| 8-K | 2.02,7.01,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| SCHEDULE 13D/A | — | Filing Doc | |
| SCHEDULE 13D/A | — | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.